Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $44.10.

A number of equities research analysts recently commented on OLMA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Friday, July 17th. Guggenheim decreased their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a research note on Friday, May 22nd. Finally, Wall Street Zen lowered shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $11.82 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. Olema Pharmaceuticals has a one year low of $4.47 and a one year high of $36.26. The business’s 50 day simple moving average is $11.46 and its two-hundred day simple moving average is $16.57. The stock has a market capitalization of $1.03 billion, a P/E ratio of -5.85 and a beta of 2.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). Analysts forecast that Olema Pharmaceuticals will post -2.22 EPS for the current year.

Insider Buying and Selling

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the transaction, the director owned 715,270 shares of the company’s stock, valued at $8,282,826.60. This represents a 1.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 12.56% of the stock is owned by insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC purchased a new position in shares of Olema Pharmaceuticals during the first quarter valued at approximately $172,000. Goldman Sachs Group Inc. raised its holdings in shares of Olema Pharmaceuticals by 93.6% during the first quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock valued at $2,787,000 after acquiring an additional 358,412 shares in the last quarter. Jane Street Group LLC lifted its stake in Olema Pharmaceuticals by 216.8% in the first quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock worth $521,000 after acquiring an additional 94,815 shares during the period. Geode Capital Management LLC lifted its stake in Olema Pharmaceuticals by 22.4% in the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after acquiring an additional 242,997 shares during the period. Finally, Creative Planning bought a new stake in Olema Pharmaceuticals in the second quarter valued at $83,000. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.